Eli Lilly and Company (SWX:LLY)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 539.37B |
| Revenue (ttm) | 43.32B |
| Net Income (ttm) | 9.82B |
| Shares Out | n/a |
| EPS (ttm) | 10.86 |
| PE Ratio | 54.94 |
| Forward PE | 28.44 |
| Dividend | 4.81 (0.84%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | n/a |
| Average Volume | 4 |
| Open | n/a |
| Previous Close | 570.00 |
| Day's Range | n/a |
| 52-Week Range | 660.00 - 830.00 |
| Beta | 0.33 |
| RSI | 22.44 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Tech sector leads: Nvidia and Amazon surge amidst healthcare tumble
Sector Overview The stock market is exhibiting diverse patterns today, with notable sector-specific performance highlighting varying investor outlooks. Technology Storms Ahead: The technology sector i...
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and el...
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...
Trump calls out weight-loss drugs as target of price-cut push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
4 stocks to watch on Monday: AAPL, NRG, FOX/FOXA and LLY
Pfizer, Eli Lilly, Merck and Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly's Zepbound outshines Wegovy in a Phase 3b trial, delivering superior weight loss results.
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs came out in favor of Eli Lilly over its rival Novo Nordisk.
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company’s (NYSE: LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE: NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants tre...